Clinical trial
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple…
NCT00317798 · University of Rochester, Other · Completed
Key facts
| NCT number | NCT00317798 |
|---|---|
| Title | Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma |
| Official title | A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM) |
| Lead sponsor | University of Rochester, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | anti-thymocyte globulin, sirolimus |
| Enrollment | 18 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Apr 25, 2006 |
| Last update posted | Aug 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: